Prion protein-dendrimer conjugates for use in treatment of alzheimer disease
US10815292B2 · kind B2 · utility
0Cited by
0References
18Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | May 10, 2017 |
| Grant date | Oct 27, 2020 |
| Priority date | — |
| Expiry date | May 10, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to PrP-derived peptide fragments with SEQ ID NO: 1 or SEQ ID NO: 2 or SEQ ID NO: 3 or SEQ ID NO: 4 for use as a medicament in the treatment of Aβ amyloidogenesis-related pathologies and/or Aβ-related toxicity, in particular of Alzheimer disease (AD), to a conjugate comprising PrP-derived peptide fragments with SEQ ID NO: 1 or SEQ ID NO: 3 and/or SEQ ID NO: 2 or SEQ ID NO: 4 and a carrier molecule, wherein the carrier molecule is a pharmacologically admissible molecule, preferably a low-generation dendrimer such as PAMAM dendrimer, and a method of manufacturing the above conjugate.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.